|
Canada-0-TileNonCeramicDistributors företaget Kataloger
|
Företag Nyheter:
- Suvorexant - ALZFORUM
Suvorexant is taken by mouth Suvorexant was reported to have a lower potential for abuse, and be generally safer, than other sleep medications frequently used in aging populations, such as benzodiazepines (Okino et al , 2023; Moline et al , 2023; Pan et al , 2023; Katsuta et al , 2023) Orexin is a neuropeptide produced by the hypothalamus
- Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human . . .
Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, Mawuenyega KG, Bollinger JG, Ovod V, Barthélemy NR, Bateman RJ Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS Ann Neurol 2023 Jul;94 (1):27-40 Epub 2023 Apr 20 PubMed
- Polysomnographic assessment of suvorexant in patients with probable . . .
Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
- Seltorexant - ALZFORUM
Background Seltorexant is a selective antagonist of the human orexin-2 receptor The neuropeptide orexin regulates wakefulness; inhibiting orexin receptor signaling promotes sleep This drug is in advanced clinical development for treating depression, where it is thought to be effective by improving sleep It is being tested to treat agitation and aggression in people with AD
- Suvorexant ameliorates cognitive impairments and pathology in APP PS1 . . .
Zhou F, Yan XD, Wang C, He YX, Li YY, Zhang J, Wang ZJ, Cai HY, Qi JS, Wu MN Suvorexant ameliorates cognitive impairments and pathology in APP PS1 transgenic mice Neurobiol Aging 2020 Jul;91:66-75 Epub 2020 Mar 3 PubMed
- Lemborexant ameliorates tau-mediated sleep loss and neurodegeneration . . .
This is a very interesting and important study The findings suggest that orexin antagonism reduces tau-mediated neurodegeneration by reducing tau phosphorylation These results support what my lab reported in 2023, when we found that suvorexant, another dual orexin receptor antagonist, reduced tau phosphorylation in human CSF Since suvorexant did not increase sleep compared to placebo, we
- Dual orexin receptor antagonists for treatment of insomnia: A . . .
Khazaie H, Sadeghi M, Khazaie S, Hirshkowitz M, Sharafkhaneh A Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
- Drug Reported to Help Alzheimer’s Patients Sleep Better
Suvorexant met both its primary and secondary efficacy endpoints, improving total sleep time and shortening wake time in the middle of the night At baseline, people on drug slept an average of 278 minutes, similar to the 274 minutes for those on placebo
- Pilot evaluation of a consumer wearable device to assess sleep in a . . .
Svetnik V, Wang TC, Ceesay P, Snyder E, Ceren O, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D, Herring WJ Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease J Sleep Res 2021 Dec;30 (6):e13328 Epub 2021 Aug 2 PubMed
- Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data . . .
Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials Am J Geriatr Psychiatry 2017 Jul;25 (7):791-802 Epub 2017 Mar 8 PubMed
|
|